Objective: The purpose of this study was to ascertain the impact of obesity on the cost of disease management in people with or at high risk of atherothrombotic disease from a governmental perspective using a bottom-up approach to cost estimation. In addition, the aim was also to explore the causes of any differences found. Method: The health-care costs of obesity were estimated from 2819 participants recruited into the nationwide Australian REACH Registry with established atherothrombotic disease or at least three risk factors for atherothrombosis. Enrollment was in 2004, through primary care general practices. Information was collected on the use of cardiovascular drugs, hospitalizations and ambulatory care services. 'Bottom-up' costing was undertaken by assigning unit costs to each health-care item, based on Australian Government-reimbursed figures 2006-2007. Linear-mixed models were used to estimate associations between direct medical costs and body mass index (BMI) categories. Results: Annual pharmaceutical costs per person increased with increasing BMI category, even after adjusting for gender, age, living place, formal education, smoking status, hypertension and diabetes. Adjusted annual pharmaceutical costs of overweight and obese participants were higher ($7 (P ¼ 0.004) and $144 (o0.001), respectively) than those of the normal weight participants. This was due to participants in higher BMI categories receiving more pharmaceuticals than normal weight participants. There was no significant change across the BMI categories in annual ambulatory care costs and annual hospital costs. Conclusion: In these participants with or at high risk of atherothrombotic disease, annual pharmaceutical costs were greater in participants of higher BMI category, but there was not such a gradient in the annual hospital or ambulatory care costs. The greater cardiovascular pharmaceutical costs for participants of higher BMI categories remained even after adjusting for a range of demographic factors and comorbidities. Our results suggest that these costs are explained by the higher number of drugs used among people with atherothrombotic disease. Further investigation is needed to understand the reasons for this level of drug use.
Introduction
Obesity has been linked to a higher annual medical expenditure. [1] [2] [3] [4] [5] [6] [7] In Australia, the cost of obesity in 2005 was an estimated $AUD3.7 billion, of which $AUD870 million were direct costs to the government. 8 However, many studies on which such findings are based use a 'top-down' approach to cost estimation and have obtained their figures from inpatient settings or hypothetical scenarios. 5, 9 Little is known about the actual individual medical costs of obesity based on a 'bottom-up' approach to cost estimation. Furthermore, few studies have explored the causes of the difference in cost by body weight. 1 Finkelstein et al. 10 reported that comorbidities such as diabetes and dyslipidemia partly explain the incremental increase in medical costs associated with obesity, particularly at older ages. Raebel et al. 1 found that the greater costs among obese patients can be largely attributed to greater costs of prescription medication. However, it is unknown to what extent costs increase with increasing body weight independent of disease groups or comorbidities such as these. Without such information, health-care policy makers cannot make informed decisions regarding the allocation of resources to the management and treatment of obesity, and treatment of comorbidities. The aims of this study are (1) to ascertain the impact of obesity on the cost of disease management in people with or at high risk of atherothrombotic disease from a governmental perspective using a bottom-up approach to cost estimation; and (2) to explore the causes of any differences found. Our data are obtained from a follow-up registry of people with or at high risk of atherothrombotic disease in Australia.
Methods
The REACH Registry The REACH Registry is an international, prospective, observational registry designed to obtain information on the management of participants with or at high risk of atherothrombosis. This study used data from the Australian component of the REACH Registry, based on an international REACH study protocol, the details for which have been published elsewhere. 11, 12 However, the Australian component of REACH is unique in that it is being undertaken entirely in general practices rather than in other specialties. 13 General practitioners (GPs) were identified using university, General Practice Division and pharmaceutical industry databases in five Australian mainland states. Letters of invitation were sent to GPs, and those GPs expressing an interest in participating in the registry were visited by a REACH Registry study coordinator. Participating GPs accommodated REACH Registry study nurses within their practices for the purposes of screening participants. Participants were subsequently invited by a letter to attend an initial screening visit at their usual general practice, where a study nurse reviewed medical records. Participants were recruited consecutively, and each participating GP recruited a maximum of 15 participants. Baseline measurements (height, weight, waist circumference, and seated systolic and diastolic blood pressure) were obtained by a trained nurse. The clinical events that occurred during the follow-up period of up to 3 years in duration were recorded in the REACH Registry.
Study population
The baseline recruitment process commenced between March and June 2004. Participants were eligible for enrollment if they were aged 45 years or older and had either established atherothrombotic disease (comprising any of coronary artery disease, cerebrovascular disease and peripheral arterial disease) or at least three cardiovascular risk factors. More details regarding the inclusion criteria for established disease has been described in detail elsewhere. The risk factors used for enrollment consisted of treated type 1 and 2 diabetes or history of diabetes, asymptomatic carotid stenosis of 70% or higher, carotid intima-media thickness of two or more adjacent sites, systolic blood pressure of at least 150 mm Hg despite therapy for at least 3 months, hypercholesterolemia treated with medication, current frequent smoking (X15 cigarettes per day), and age 65 years or older (men) or 70 years or older (women). 13 Data were collected on an internationally standardized case report form. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg m . Systolic and diastolic blood pressure was measured in a seated position after at least 5 min of rest. Fasting blood glucose and fasting total cholesterol levels were based on participants' medical histories within the past 12 months. Smoking status was based on previous or current smoking status or at least five cigarettes per day within the last month before enrollment. Information on formal education and living place of participants were collected through a case report form.
The Australian REACH Registry consisted of 2873 participants. In this analysis, participants whose BMI was lower than 18.5 kg m À2 were excluded, as underweight has been shown to have an inverse relationship with CVD morbidity and mortality. 14 Ambulatory care services and data collection Information regarding frequency of attendance at GPs and frequency of use of imaging/pathology and rehabilitation services was also gathered by case note review, participant interview and recorded on the internationally standardized case report form.
Costs
All estimations of health-care-related costs were made from the perspective of the government, this being at Federal level for pharmaceuticals and State level for hospitalizations. Copayments and costs related to private health-care admissions were not considered, given this study sought to estimate the cost to the government as part of total health-care costs to society. 'Bottom-up' costing was undertaken by assigning unit costs to each health-care item. 16 The estimated direct health-care costs of obesity were those of direct relevance to the management of each atherothrombotic condition. Data were not available in the REACH Registry on all individual direct costs related to obesity.
Pharmaceutical costs. Data inputs regarding direct pharmaceutical costs were sourced from the Pharmaceutical Benefit Scheme, Australia's pharmaceutical reimbursement program. Data analyzed were relevant to the period September 2006 to September 2007. For each therapeutic class, we estimated a weighted average daily cost by calculating the sum-product of the cost of each drug dose and its proportional market share, as indicated by the Pharmaceutical Benefit Scheme. Market share data from the Pharmaceutical Benefit Scheme were used, as data from the REACH Registry were only available by level of therapeutic class rather than for individual drugs. 17 Pharmaceutical cost calculations are best described using a simple hypothetical example, if a therapeutic class comprised two possible doses, with respective annual costs of $AUD1500 and $AUD2000 and respective market shares of 70 and 30%, then the weighted average annual cost of that class was (70% Â $1500) þ (30% Â $2000) ¼ $1650. 15, 18 The daily doses used reflected current treatment guidelines and the annual costs were estimated by multiplying daily costs by 365.25. The assumption underpinning the conversion of daily to annual costs was that patients remained compliant with their medications throughout the year. Appendix 1 shows classes of medications used by participants in the REACH Registry, and describes average daily and yearly costs of drugs.
Hospital costs. Costs were estimated by assigning each hospitalization to its relevant diagnosis related group (DRG). 19 The DRGs were developed as homogeneous clinical and resource categories for groups of patients treated, based on services used, and provide a basis for payment purposes such as case-mix funding. Using DRGs, a case-mix funding system is one tool that can be used to identify the size of the reimbursement of health authorities to public hospitals in Australia. 20 Therefore, the hospital budget can be determined mainly by performance or output instead of negotiation and politics. 21 Average weighted costs were calculated if the unit cost for each clinical event or vascular intervention comprised multiple DRGs. The national cost weight data for each DRG item were used. DRG weights are adjusted for high outliers with respect to length of stay. Appendix 2 shows DRG items used by individual participants in the REACH Registry.
Ambulatory care costs. These costs were estimated using the Medicare Benefit Schedule (MBS), and were relevant to the period 2006-2007. The MBS is a listing of the health services subsidized by the Australian government and is part of the wider Medicare Benefits Scheme managed by the Department of Health and Ageing and administered by Medicare Australia.
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The same approach was used to calculate the ambulatory care costs. If unit costs for each service comprised multiple codes, then the average weighted cost of these codes was calculated based on the reimbursement scheme and market share. The weighted average costs for each service used were then summed to calculate the estimated expenditures incurred by each patient in the REACH Registry. Appendix 3 describes MBS items used by individual participants in the REACH Registry.
Statistical analysis
Direct medical costs (cardiovascular pharmaceutical, hospital and other outpatient costs) were reported in tables as means with 95% confidence intervals. Other continuous variables were reported as means (with standard deviations) and categorical variables were reported as percentages.
Participants are clustered by GP, so associations between the medical costs, the numbers of drugs used and BMI categories are based on multilevel models incorporating a random effect term for GPs. This allows a within-practice variance component to be estimated.
Linear mixed models were used to estimate associations between the use of direct medical costs (cardiovascular pharmaceutical, hospital and other outpatient costs) and BMI categories, with adjustment for age, gender, smoking status, living place, formal education, hypertension, diabetes, dyslipidemia and vascular disease and a normally distributed random effect term for GPs. For each predictor variable, the value of the resulting statistical coefficient Results Table 1 summarizes demographic and clinical characteristics of the Australian REACH Registry participants by BMI category. The average age of participants was approximately 73 years across all BMI categories. The percentage of men and percentage of current smokers was similar in all BMI categories. The prevalence of hypertension, dyslipidemia and diabetes was significant among overweight and obese participants. The prevalence of atherothrombotic disease was not significantly higher among obese participants. The prevalence of cerebrovascular disease only and peripheral arterial disease only was more common in participants with normal weight than in those in higher BMI categories.
Normal weight patients were more likely than overweight or obese participants to live in suburban areas, whereas obese participants were most likely to live in rural areas. With regard to formal education, normal weight participants were more likely to have finished college or university and less likely to have only 1-12 years of formal education.
As shown in Figure 1 , annual cardiovascular pharmaceutical costs were higher among overweight and obese participants, but there was no significant change across BMI categories in annual ambulatory care costs and annual hospital costs. Table 2 indicates the extent to which annual pharmaceutical costs increased with increasing BMI categories independent of disease groups or comorbidities. Annual pharmaceutical costs were higher among overweight and obese participants, even after adjusting for gender, age, living place, formal education, smoking status, hypertension and diabetes. Model 4 indicates that after adjustment for these factors, the annual pharmaceutical costs of overweight and obese participants were higher than those of normal weight participants ($87 (P ¼ 0.004) and $144 (o0.001), respectively).
In Model 5, the higher pharmaceutical costs in overweight participants compared with normal weight participants was no longer present after adjusting for dyslipidemia. However, this difference remained between obese and normal weight participants. In Model 6, the higher pharmaceutical costs in obese participants compared with normal weight participants remained even after adjustment for vascular diseases.
The consistency of annual hospital and ambulatory care costs across the BMI categories remained even after adjusting for these comorbidities and demographic factors (Tables 3  and 4 ). For example, after adjusting for each of these variables, the annual hospital costs for obese participants were less (À$136, (P ¼ 0.612)) compared with the normal weight participants; however, the difference was not statistically significant. Table 5 indicates the mean number of drugs used in each BMI category among participants with a variety of risk factors but no established disease and for those with selected types of established disease. The P-value reported shows whether there is a statistically significant variation between BMI categories in the mean number of drugs used after Participants in higher BMI categories received more pharmaceuticals than normal weight participants with the same condition. However, after adjustment for demographic variables and comorbidities this difference was only statistically significant for the overall cohort (P ¼ 0.013). In this case, the average number of drugs used in participants with normal weight was 3.9, overweight 4.3 and obese 4.9 (Table 5) .
Discussion
Among participants with or at high risk of atherothrombotic disease, annual cardiovascular pharmaceutical costs were higher among participants with a higher BMI category. However, there was not such a gradient in the relationship between annual ambulatory care costs or hospital costs and BMI categories. The higher cardiovascular pharmaceutical costs for participants in higher BMI categories remained even after adjusting for a range of demographic factors and comorbidities. These results suggest that the differences seen may be explained by a higher number of drugs used at baseline for the same condition among participants with atherothrombotic disease.
There are a number of potential explanations for the greater number of drugs used by participants in higher BMI categories. A previous study suggested that there is some evidence that patients of higher body weight are more likely to be treated medically rather than surgically. 24 Furthermore, obese patients may be in need of more drugs due to a greater severity of disease. 8 This explanation is supported to some extent by the higher (although not significantly higher) rate of risk factors (hypertension, dyslipidemia and diabetes) in those with higher body weights. However, even if they were receiving more drugs for this reason, the persistence of this gradient suggests that their risk factors remained higher. It is also possible that participants with higher body weights were prescribed a greater number of drugs due to an appearance suggestive of being at higher risk. This is one of the key findings of this study and further research is needed to better understand the reasons for this level of drug use. The lack of a positive relationship between annual ambulatory care and hospitalization costs across the range of body weight may also be explained by the higher prevalence of vascular disease in normal weight participants. Some previous studies have reported higher hospital costs for obese Economic implications of obesity Z Ademi et al patients. 1, 5 However, Hauck and Hollingsworth 24 showed that the difference in hospital costs between nonobese and obese patients is specialty dependent, in that there are a number of specialties in which obese patients stay no longer in hospital on average than normal weight patients. 24 Obese patients in medically managed specialties had shorter lengths of stay, and those in surgically managed specialties had longer lengths of stay, compared to a nonobese population. The sampling in the Australian REACH Registry was conducted through GP locations, and as such included relatively stable outpatients as opposed to inpatients. 13 Therefore, these results may not reflect the true prevalence of obesity in Australia among all atherothrombotic patients.
Estimated pharmaceutical costs were limited to cardiovascular medications. There are other related pharmaceutical costs that were not reported, as this was not a primary focus.
Some assumptions made about pharmaceutical costs were necessary in this study and costs of each class were based on current patterns of use in Australia. Inaccuracy in the estimated pharmaceutical costs would rise only if the use of these medicines was not representative of use in the general Australian population. 18 However, this is unlikely as the medicine use in the REACH Registry was consistent with the Australian Institute of Health and Welfare report on the use of cardiovascular medicines. 25 Using DRG cost weights was necessary as our hospital data were from patients reporting outcomes within a 1-year period of follow-up. However, DRG codes capture only costs associated within a single hospital episode and therefore do not reflect the subsequent transfers between hospitals or explain increases in the resource use in the other part of health care. 20 The lack of this information may have potentially prevented the finding of a true difference in hospital costs and might only have resulted in an underestimate of costs related with BMI categories among people with atherothrombotic disease.
The estimated health-care costs are relevant to the Australian health-care settings (in which hospitalizations are funded by State governments and pharmaceuticals funded by the Commonwealth Government) and applicable These percentages were derived from patients with elevated risk factors only (n ¼ 302) and no overt atherothrombotic disease, such as hypertension, diabetes and dyslipidemia. The percentages for CAD only, CerVD only, PAD only and 2-3 disease sites were derived from patients with established disease (n ¼ 2513).
Economic implications of obesity Z Ademi et al to people with, or at high risk of, atherothrombotic disease. Cost estimates are unlikely to reflect the equivalent costs in other countries, as health-care funding is unique to each country. However, clinical practice in Australia is similar to that in other developed countries, and the relativity of component costs is of relevance.
Out of pocket costs, although minor, and indirect costs incurred by lost productivity (also minor in this age group) were not captured, but are necessary for an estimation of the true burden of obesity 8 in atherothrombotic patients. Furthermore, costs were reported over a 1-year period, and thus the long-term health-care costs associated with obesity among atherothrombotic participants have not been examined. The strength of this study is that it uses a 'bottom-up' costing approach, which is a more accurate method of estimating costs compared with a 'top-down' approach. 16 Reporting the marginal costs associated with increasing body weight, independent of disease groups or comorbidities, provides novel and important information on the costs associated with obesity. This information can be used to inform the future allocation of resources in the management and treatment of obesity.
For participants with atherothrombotic disease, these results suggest that those with higher body weight received more drugs, leading to higher pharmaceutical costs compared with patients in lower BMI categories. Interestingly, the higher number of drugs used appears to be independent of disease, and as such the benefit of these additional drugs requires further investigation. This information is important for health decision-making as obesity is associated with higher healthcare spending, and more nuanced information regarding the causes of higher spending will help inform preventive policy. This study suggests that the cost of obesity with regard to elderly patients with or at high risk of atherothrombotic disease goes beyond that due to comorbidities such as hypertension, diabetes and dyslipidemia. The cost of obesity would be underestimated if it was based solely on comorbidities.
The implications of our findings are in terms of opportunity cost. Given limited health-care budgets, governments have to decide whom to subsidize and for which illnesses. In 2001 in Australia, there were approximately 1.4 million individuals aged over 65 years who were suffering from cardiovascular disease, 26 of whom 29.5% were considered obese. 15 If it is assumed that the pharmaceutical cost estimates reported in this study are applicable to the general Australian population aged over 65 years with CVD, then the marginal cost to the government with regard to obesity is $37 million. The question arising from this analysis is whether the additional drugs (costing $37 million) used by the obese participants provide additional benefit, or whether the funding of these drugs would be more beneficially allocated elsewhere.
Conclusion
In these participants with or at high risk of atherothrombotic disease annual pharmaceutical costs were higher for patients in higher BMI categories, but there was no such gradient in annual hospital or ambulatory care costs. The higher cardiovascular pharmaceutical costs for patients in higher BMI categories remained even after adjusting for a range of demographic factors and comorbidities. It is suggested that these higher costs can be explained by a higher number of drugs used among participants with atherothrombotic disease. Further investigation is needed to understand the reasons for this level of drug use. Economic implications of obesity Z Ademi et al
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